Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OHSS
MCID: OVR029
MIFTS: 64

Ovarian Hyperstimulation Syndrome (OHSS)

Categories: Genetic diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

About this section

MalaCards integrated aliases for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 56 12 58 73 36 29 13 54 6 43 15 39 71
Ohss 56 58 73
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous 56
Secondary Meig's Syndrome 12

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
symptoms occur only during pregnancy (usual onset after 6 weeks gestation)
major fluid shifts may occur in severe cases


HPO:

31
ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:5425
OMIM 56 608115
KEGG 36 H01039
MeSH 43 D016471
SNOMED-CT 67 129635004
MESH via Orphanet 44 D016471
ICD10 via Orphanet 33 N98.1
UMLS via Orphanet 72 C0085083
Orphanet 58 ORPHA64739
MedGen 41 C0085083
UMLS 71 C0085083
Sources

Summaries for Ovarian Hyperstimulation Syndrome

About this section
KEGG : 36 Ovarian hyperstimulation syndrome (OHSS) is typically an iatrogenic complication of ovulation induction (OI) occurring during the luteal phase or early pregnancy. OHSS is characterised by a cystic enlargement of the ovaries and an acute fluid shift from the intravascular to the third space, which may result in ascites, pleural infusions, pericardial infusion, and even generalized edema. Majority of OHSS cases have been associated with the use of gonadotrophins for OI in anovulatory women or for ovarian stimulation (OS) in the context of assisted reproductive technology (ART). Recurrent cases and familial occurrence of OHSS have been described, and different mutations in the follicle-stimulating hormone receptor (FSHr) have been reported in these cases. Polycystic ovarian syndrome (PCOS) appears to be the major predisposing factor for OHSS in a large number of studies.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to ectopic pregnancy and pericardial effusion, and has symptoms including vomiting, abdominal pain and nausea. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and p70S6K Signaling. The drugs Aspirin and Cetrorelix have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are ascites and abdominal pain

Disease Ontology : 12 An ovarian disease that is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space and has symptom abdominal pain, has symptom nausea and has symptom vomiting. This disease is an iatrogenic complication of assisted reproduction technology.

UniProtKB/Swiss-Prot : 73 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

Wikipedia : 74 Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take... more...

More information from OMIM: 608115
Sources

Related Diseases for Ovarian Hyperstimulation Syndrome

About this section

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 ectopic pregnancy 31.0 VEGFA GNRH1 FLT1 CGB5 CGA
2 pericardial effusion 30.9 VEGFA REN IL6 ALB
3 ovarian cyst 30.6 VEGFA GNRH1 CYP19A1 CGA AMH
4 central retinal vein occlusion 30.4 VEGFA IL6 F5
5 limb ischemia 30.4 VEGFA KDR IL6
6 severe pre-eclampsia 30.3 VEGFA F5 ALB
7 stroke, ischemic 30.3 VEGFA REN IL6 F5 ALB
8 precocious puberty 30.3 LHCGR GNRH1 CYP19A1
9 retinal vein occlusion 30.2 VEGFA KDR IL6 F5
10 retinal artery occlusion 30.0 VEGFA KDR IL6 FLT1 F5
11 endometriosis of ovary 30.0 GNRH1 CYP19A1 AMH
12 endometriosis 30.0 VEGFA KDR IL6 GNRH1 FSHR CYP19A1
13 estrogen excess 29.9 SHBG GNRH1 FSHR CYP19A1
14 eclampsia 29.8 VEGFA REN IL6 FLT1 ALB
15 hydronephrosis 29.7 VEGFA REN IL6 CYP19A1 ALB
16 hyperprolactinemia 29.5 SHBG INS GNRH1 CGA
17 gestational diabetes 29.4 SHBG INS IL6 ALB
18 luteoma 29.4 SHBG GNRH1 FSHR CYP19A1 CGA
19 acute cystitis 29.4 REN INS IL6 ALB
20 graves disease 1 29.4 SHBG INS ALB
21 polycystic ovary syndrome 29.3 SHBG INS GNRH1 FSHR CYP19A1 CGA
22 infertility 29.2 SHBG LHCGR GNRH1 FSHR FSHB CYP19A1
23 hyperandrogenism 29.1 SHBG INS GNRH1 CYP19A1
24 migraine with or without aura 1 29.1 REN INS IL6 ALB
25 chronic kidney disease 29.1 VEGFA REN INS IL6 ALB
26 hypothyroidism 29.1 VEGFA SHBG REN INS GNRH1 FSHR
27 placenta disease 29.1 VEGFA INS IL6 FLT1 F5 CGB5
28 hyperthyroidism 28.9 SHBG INS IL6 CGA ALB
29 vascular disease 28.6 VEGFA REN KDR INS IL6 F5
30 hypogonadism 28.4 SHBG LHCGR INS GNRH1 FSHB CYP19A1
31 pre-eclampsia 27.9 VEGFA REN KDR INS IL6 FLT1
32 amenorrhea 27.9 SHBG LHCGR INS GNRH1 FSHR FSHB
33 ovarian cancer 27.8 VEGFA LHCGR KDR INS IL6 GNRH1
34 hypogonadotropic hypogonadism 27.5 SHBG LHCGR INS GNRH1 FSHB CYP19A1
35 anovulation 27.5 SHBG INS GNRH1 FSHR FSHB CYP19A1
36 myocardial infarction 27.3 VEGFA SHBG REN KDR INS IL6
37 ovarian disease 26.8 VEGFA SHBG REN LHCGR INS IL6
38 capillary leak syndrome 11.8
39 thrombosis 10.7
40 thrombophilia due to thrombin defect 10.6
41 adenoma 10.5
42 anorchia 10.5 CGB5 CGA
43 adult respiratory distress syndrome 10.5
44 thrombophilia 10.5
45 hemopericardium 10.5
46 pituitary adenoma 10.5
47 mucinous cystadenofibroma 10.5 LHCGR FSHR
48 leydig cell hypoplasia 10.5 LHCGR CGA
49 sudden sensorineural hearing loss 10.4 IL6 F5
50 septate uterus 10.4 KDR FLT1

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:



Diseases related to Ovarian Hyperstimulation Syndrome
Sources

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

About this section

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 58 31 hallmark (90%) Very frequent (99-80%) HP:0001541
2 abdominal pain 58 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 increased circulating gonadotropin level 58 31 hallmark (90%) Very frequent (99-80%) HP:0000837
4 enlarged polycystic ovaries 58 31 hallmark (90%) Very frequent (99-80%) HP:0008675
5 hirsutism 58 31 hallmark (90%) Very frequent (99-80%) HP:0001007
6 abdominal distention 58 31 hallmark (90%) Very frequent (99-80%) HP:0003270
7 increased serum testosterone level 58 31 hallmark (90%) Very frequent (99-80%) HP:0030088
8 nausea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002018
9 capillary leak 58 31 hallmark (90%) Very frequent (99-80%) HP:0030005
10 pleural effusion 58 31 frequent (33%) Frequent (79-30%) HP:0002202
11 hemorrhagic ovarian cyst 58 31 frequent (33%) Frequent (79-30%) HP:0012886
12 peripheral edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0012398
13 pulmonary edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100598
14 hypovolemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011106
15 generalized edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0007430
16 nausea and vomiting 58 Very frequent (99-80%)
17 abnormality of the genitourinary system 31 HP:0000119
18 ovarian cyst 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

56
Abdomen:
ascites
abdominal pain

Genitourinary Internal Genitalia Female:
enlarged multilocular ovaries
pathology shows multiple serous and hemorrhagic follicular cysts lined by luteinized cells ('hyperreactio luteinalis')
ovaries return to normal size after delivery

Abdomen Gastrointestinal:
nausea

Clinical features from OMIM:

608115

Symptoms:

12
  • • vomiting
  • • abdominal pain
  • • nausea

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:


abdominal pain, nausea

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ALB AMH CDH5 CGA CYP19A1 F5
2 endocrine/exocrine gland MP:0005379 10.32 ALB AMH BMP15 CDH5 CGA CYP19A1
3 cardiovascular system MP:0005385 10.31 ALB CDH5 CYP19A1 F5 FLT1 FSHR
4 growth/size/body region MP:0005378 10.31 CDH5 CGA CYP19A1 F5 FLT1 FSHR
5 cellular MP:0005384 10.26 ALB CDH5 CYP19A1 FLT1 FSHB FSHR
6 hematopoietic system MP:0005397 10.22 CDH5 CYP19A1 FLT1 FSHR GNRH1 IL6
7 immune system MP:0005387 10.21 ALB CDH5 CYP19A1 FLT1 FSHR GNRH1
8 liver/biliary system MP:0005370 10.07 ALB CDH5 CYP19A1 F5 GNRH1 IL6
9 integument MP:0010771 10.06 CDH5 CYP19A1 F5 FSHR GNRH1 IL6
10 nervous system MP:0003631 10.03 CGA CYP19A1 F5 FLT1 FSHR GNRH1
11 muscle MP:0005369 9.92 ALB CYP19A1 FLT1 IL6 INS KDR
12 normal MP:0002873 9.81 ALB CDH5 CYP19A1 FLT1 GNRH1 INS
13 renal/urinary system MP:0005367 9.56 ALB CYP19A1 GNRH1 IL6 INS LHCGR
14 reproductive system MP:0005389 9.47 AMH BMP15 CDH5 CGA CYP19A1 FLT1
Sources

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

About this section

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Cabergoline Approved Phase 4 81409-90-7 54746
5
Ganirelix Approved Phase 4 123246-29-7, 124904-93-4 25081094
6
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
7
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
8
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
9
leucovorin Approved Phase 4 58-05-9 6006 143
10
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
11
Buserelin Approved, Investigational Phase 4 57982-77-1
12
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
13
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15 Fibrinolytic Agents Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Platelet Aggregation Inhibitors Phase 4
19 Analgesics Phase 4
20 Antipyretics Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Antirheumatic Agents Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Pharmaceutical Solutions Phase 4
25 Dopamine agonists Phase 4
26 Antiparkinson Agents Phase 4
27 Dopamine Agents Phase 4
28 Neurotransmitter Agents Phase 4
29 Triptorelin Pamoate Phase 4
30 Contraceptive Agents Phase 4
31 Progestins Phase 4
32 Hypoglycemic Agents Phase 4
33 Hormone Antagonists Phase 4
34 Estrogen Antagonists Phase 4
35 Estrogen Receptor Antagonists Phase 4
36 Alpha-lipoic Acid Phase 4
37 Thioctic Acid Phase 4
38 Aromatase Inhibitors Phase 4
39 Vitamins Phase 4
40 Antineoplastic Agents, Hormonal Phase 4
41 Chorionic Gonadotropin Phase 4
42 Trace Elements Phase 4
43 Micronutrients Phase 4
44 Vitamin B Complex Phase 4
45 Hematinics Phase 4
46 Folate Phase 4
47 Nutrients Phase 4
48 Vitamin B9 Phase 4
49 Prolactin Release-Inhibiting Factors Phase 4
50 Follicle Stimulating Hormone Phase 4

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Preventive Application of GnRH Antagonist on Early Ovarian Hyperstimulation Syndrome in High-risk Women: A Prospective Randomized Trial Unknown status NCT03188471 Phase 4 GnRH antagonist;aspirin
2 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
3 A Prospective Randomized Study Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Administration in Patients at Risk for Severe OHSS Unknown status NCT01347268 Phase 4
4 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
5 Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients Unknown status NCT00415792 Phase 4 Arvekap, Pregnyl
6 Corifollitropin Alfa (Elonva) Versus Follitropin Beta in High Responders: A Randomized Controlled Trial Unknown status NCT02471677 Phase 4 Elonva;Puregon
7 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
8 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
9 Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer Unknown status NCT03309436 Phase 4 Clomiphene Citrate protocol
10 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Unknown status NCT02703649 Phase 4 Letrozole
11 Prospective Randomized Trial on GnRH Agonist Triggering Versus hCG Triggering in IVF Stimulation in PCOS Patients Unknown status NCT01683513 Phase 4 GnRh agonist +1500E hCG
12 A Phase IV Study on the Effect of Luteal Supplementation With Rec-LH on the Pregnancy Rate After Ovulation Triggering With GnRH-agonist Instead of HCG in IVF Protocol;Proof of Concept Unknown status NCT00954811 Phase 4 300IU rec-LH;progesterone 600mg
13 Follicular Fluid, Serum Endocrine Profile Following Stimulation With Recombinant Gonadotropins or Highly Purified Human Menopausal Gonadotropin During GnRH-antagonist Protocol Unknown status NCT02992808 Phase 4 recombinant gonadotropins;HP-HMG
14 Coasting Versus Gonadotrophin-Releasing Hormone Antagonist Administration in Patients at High Risk of Ovarian Hyperstimulation Syndrome and Its Impact on the Embryos Quality and the Outcome of ICSI Completed NCT03996434 Phase 4 Gonadotropin;Antagonist
15 Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
16 Endometrial Advancement After Rec or u-HCG Triggering Completed NCT00953628 Phase 4 10000 IU urinary HCG;250 mcg recombinant HCG
17 A Prospective Randomized Study Comparing the Use of hCG or GnRH Agonist to Trigger Final Oocyte Maturation in High Responders Undergoing in-Vitro Fertilization Treatment Completed NCT00349258 Phase 4 Leuprolide acetate
18 A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
19 Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
20 The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment Completed NCT02670304 Phase 4 letrozole;Aspirin
21 The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation in Women Undergoing Assisted Reproduction Completed NCT01065376 Phase 4
22 Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization Completed NCT01233206 Phase 4 Metformin;Placebo administration
23 An Efficacy and Safety Study of Corifollitropin Alfa Versus Daily Follitropin Beta for Controlled Ovarian Stimulation in Women 35-42 Years Old With a Body Weight ≥ 50 kg Undergoing IVF Treatment. Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
24 A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II) Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
25 Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG Completed NCT01638026 Phase 4 TRIPTORELIN ACETATE, hCG
26 Synchronization of Follicle Wave Emergence and Ovarian Stimulation in Women With a History of Poor Ovarian Response to Treatment Completed NCT00439829 Phase 4 Gonal F;Luveris;Cetrotide;hCG
27 GnRH Agonist and Antagonists in an Oocyte Donation Program Completed NCT00505817 Phase 4 Cetrorelix and Leuprolide
28 A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl) Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
29 Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct and GnRH Agonist Trigger for Egg Bank Donation Completed NCT02069808 Phase 4 Follistim;Ganirelix;Menotropins;Leuprolide
30 Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders; a Randomized Controlled Trial Completed NCT03759301 Phase 4 Growth Hormones Somatropin Recombinant;Placebo saline solution
31 Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist Completed NCT01607203 Phase 4 Decapeptyl Daily;pregnyl
32 Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
33 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Completed NCT03118830 Phase 4 Triptorelin;cetrorelix;Recombinant Follicle Stimulating Hormone
34 Clinical Use of the Perifollicular Vascularity Assessment in in-Vitro Fertilization Cycles: a Pilot Study Completed NCT00458380 Phase 4
35 The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies: A Prospective Randomized Controlled Trial Recruiting NCT03169166 Phase 4 Triptorelin
36 Effect of Myo-Inositol- Based Co-treatment on Oocyte Quality in Women With Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
37 Dual Trigger Versus Gonadotropin Releasing Hormone Agonist Trigger Combined With Luteal Human Chorionic Gonadotropin Administration Recruiting NCT02330770 Phase 4 GnRHa and HCG;GnRHa then HCG (single low-dose);GnRHa then HCG (multiple low-doses)
38 A Randomized Controlled Trial of Pre-retrieval Triggering Methods in in Vitro Fertilization Patients Classified as Low, Normal or High Responder Recruiting NCT02715336 Phase 4 Ovulation induction with hCG and Lupron (GnRH agonist)
39 Follicular Synchronization in Polycystic Ovarian Syndrome Patients Undergoing Intracytoplasmatic Sperm Injection With Letrozole /Antagonist Protocol: A Randomized Controlled Trial Recruiting NCT04069117 Phase 4 letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
40 Follicle Stimulating Hormone (FSH) Followed by Human Menopausal Gonadotropin (HMG) Versus FSH Plus HMG During Controlled Ovarian Stimulation for in Vitro Fertilization Recruiting NCT04385342 Phase 4 FSH;HP-hMG
41 Does Use of Letrozole in Controlled Ovarian Stimulation in Normal Ovarian Responder in Fresh Embryo Transfer IVF/ICSI Cycle Improve the Pregnancy Rate? Active, not recruiting NCT03901170 Phase 4 Letrozole 2.5mg
42 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
43 The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
44 Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART Suspended NCT00646893 Phase 4
45 An Uncontrolled, Open-label Feasibility Study to Demonstrate That a GnRH Agonist (Decapeptyl) Can be Safely Administered to Trigger Final Oocyte Maturation in High Responder Patients to Mitigate the Risk of OHSS Terminated NCT01714648 Phase 4 Triptorelin 0.2 mg
46 Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF) Terminated NCT02221154 Phase 4
47 A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG) Terminated NCT01606709 Phase 4 GnRH agonist;hCG
48 A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
49 Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology [ART: In Vitro Fertilization (IVF)/ Intracytoplasmic Sperm Injection (ICSI)] With GONAL-f® Terminated NCT01210144 Phase 4 Gonal -f® [r-hFSH];Ovitrelle® [r-hCG alfa];Gonadotropin-releasing hormone (GnRH) Agonist;Gonadotropin-releasing hormone (GnRH) Antagonist
50 Age Versus Ovarian Reserve Markers Based Therapy in IN Vitro Fertilization Terminated NCT01816789 Phase 4 rFSH;buserelin

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ganirelix
Ganirelix acetate

Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Sources

Genetic Tests for Ovarian Hyperstimulation Syndrome

About this section

Genetic tests related to Ovarian Hyperstimulation Syndrome:

# Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 29 FSHR
Sources

Anatomical Context for Ovarian Hyperstimulation Syndrome

About this section

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

40
Ovary, Endothelial, Pituitary, Liver, Breast, Testes, Kidney
Sources

Publications for Ovarian Hyperstimulation Syndrome

About this section

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 3022)
# Title Authors PMID Year
1
Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. 56 6 54 61
17721928 2008
2
A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. 61 54 6 56
12930927 2003
3
Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. 6 61 56 54
12930928 2003
4
Spontaneous ovarian hyperstimulation syndrome in four consecutive pregnancies. 6 61 56
8894317 1996
5
Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. 54 61 6
16278261 2006
6
A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. 6 61 54
15080154 2004
7
Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. 54 61 6
9402264 1997
8
Spontaneous ovarian hyperstimulation syndrome presenting with acute abdomen. 56 61
16679690 2006
9
Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. 6 61
15579795 2004
10
The pathogenesis of the ovarian hyperstimulation syndrome. 56 61
12930924 2003
11
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. 56 61
12498425 2002
12
A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. 6
15886248 2005
13
Follicle-stimulating-hormone receptor and twinning. 6
11213123 2001
14
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. 54 61
20423279 2010
15
Ovarian hyperstimulation syndrome (OHSS) due to mutations in the follicle-stimulating hormone receptor. 54 61
20362966 2010
16
Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. 61 54
19800620 2010
17
Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. 61 54
19342033 2010
18
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. 54 61
20139430 2010
19
Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. 54 61
20008399 2010
20
[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. 54 61
20209851 2009
21
GnRHa to trigger final oocyte maturation: a time to reconsider. 54 61
19608565 2009
22
GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. 61 54
19909588 2009
23
A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats. 61 54
19443574 2009
24
Insights into angiogenic imbalances during pregnancy. 61 54
19622952 2009
25
Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? 61 54
19573290 2009
26
[Analysis of the clinical outcomes of IVF-ET treatment in infertile patients with polycystic ovary syndrome or polycystic ovaries]. 54 61
19460721 2009
27
Miscarriage and clinical correlates of leukocyte count in patients with ovarian hyperstimulation syndrome. 61 54
19835500 2009
28
GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. 61 54
18692821 2009
29
Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. 54 61
19088107 2009
30
Possible familial gestational spontaneous ovarian hyperstimulation syndrome due to mutation of FSH receptors (FGSOHS). 54 61
19391457 2009
31
Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. 61 54
19192339 2009
32
In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols. 54 61
18321490 2009
33
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. 61 54
18367175 2009
34
Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. 54 61
18321487 2009
35
Human corpus luteum physiology and the luteal-phase dysfunction associated with ovarian stimulation. 54 61
19406027 2009
36
Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. 61 54
19146764 2009
37
High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. 54 61
19688946 2009
38
The luteal phase after 3 decades of IVF: what do we know? 54 61
20034417 2009
39
Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. 54 61
19017414 2008
40
Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. 61 54
18439601 2008
41
Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. 61 54
19102964 2008
42
Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? 61 54
18166181 2008
43
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. 54 61
18385260 2008
44
Role of human albumin in ovarian hyperstimulation syndrome. 54 61
18468600 2008
45
Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. 54 61
18400585 2008
46
Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. 61 54
18230195 2008
47
Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. 61 54
18171700 2008
48
Spontaneous ovarian hyperstimulation in a naturally conceived pregnancy with uncontrolled hypothyroidism. 61 54
18238999 2008
49
Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)? 54 61
18164141 2008
50
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. 61 54
18159088 2008
Sources

Variations for Ovarian Hyperstimulation Syndrome

About this section

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6 (show top 50) (show all 59) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FSHR NM_000145.3(FSHR):c.1346C>T (p.Thr449Ile)SNV Pathogenic 16249 rs28928870 2:49190614-49190614 2:48963475-48963475
2 FSHR NM_000145.3(FSHR):c.1699G>A (p.Asp567Asn)SNV Pathogenic 16250 rs28928871 2:49190261-49190261 2:48963122-48963122
3 FSHR NM_000145.3(FSHR):c.1345A>G (p.Thr449Ala)SNV Pathogenic 16252 rs121909663 2:49190615-49190615 2:48963476-48963476
4 FSHR NM_000145.3(FSHR):c.1634T>C (p.Ile545Thr)SNV Pathogenic 16253 rs121909664 2:49190326-49190326 2:48963187-48963187
5 FSHR NM_000145.3(FSHR):c.383C>A (p.Ser128Tyr)SNV Pathogenic 16254 rs121909665 2:49217768-49217768 2:48990629-48990629
6 FSHR NM_000145.4(FSHR):c.1572C>G (p.Ser524Arg)SNV Conflicting interpretations of pathogenicity 757090 2:49190388-49190388 2:48963249-48963249
7 FSHR NM_000145.3(FSHR):c.479T>C (p.Ile160Thr)SNV Conflicting interpretations of pathogenicity 16244 rs121909659 2:49216161-49216161 2:48989022-48989022
8 FSHR NM_000145.3(FSHR):c.24G>T (p.Leu8Phe)SNV Conflicting interpretations of pathogenicity 255348 rs115030945 2:49381533-49381533 2:49154394-49154394
9 FSHR NM_000145.4(FSHR):c.*321A>TSNV Conflicting interpretations of pathogenicity 897606 2:49189551-49189551 2:48962412-48962412
10 FSHR NM_000145.4(FSHR):c.1022T>C (p.Val341Ala)SNV Conflicting interpretations of pathogenicity 898832 2:49190938-49190938 2:48963799-48963799
11 FSHR NM_000145.3(FSHR):c.446+10T>CSNV Conflicting interpretations of pathogenicity 336490 rs200504733 2:49217695-49217695 2:48990556-48990556
12 FSHR NM_000145.3(FSHR):c.786C>T (p.Val262=)SNV Conflicting interpretations of pathogenicity 336485 rs150863050 2:49195905-49195905 2:48968766-48968766
13 FSHR NM_000145.3(FSHR):c.485G>A (p.Arg162Lys)SNV Conflicting interpretations of pathogenicity 336489 rs111883853 2:49216155-49216155 2:48989016-48989016
14 FSHR NM_000145.3(FSHR):c.225-11T>CSNV Uncertain significance 336492 rs886056152 2:49247310-49247310 2:49020171-49020171
15 FSHR NM_000145.3(FSHR):c.1330G>A (p.Ala444Thr)SNV Uncertain significance 336482 rs202162496 2:49190630-49190630 2:48963491-48963491
16 FSHR NM_000145.3(FSHR):c.685A>G (p.Arg229Gly)SNV Uncertain significance 336487 rs201122960 2:49196006-49196006 2:48968867-48968867
17 FSHR NM_000145.3(FSHR):c.373C>A (p.Leu125Met)SNV Uncertain significance 336491 rs886056151 2:49244629-49244629 2:49017490-49017490
18 FSHR NM_000145.3(FSHR):c.1596G>A (p.Met532Ile)SNV Uncertain significance 336480 rs757909841 2:49190364-49190364 2:48963225-48963225
19 FSHR NM_000145.3(FSHR):c.1030G>C (p.Val344Leu)SNV Uncertain significance 336483 rs772756688 2:49190930-49190930 2:48963791-48963791
20 FSHR NM_000145.3(FSHR):c.947A>G (p.Glu316Gly)SNV Uncertain significance 336484 rs886056150 2:49191013-49191013 2:48963874-48963874
21 FSHR NM_000145.4(FSHR):c.956A>G (p.Glu319Gly)SNV Uncertain significance 898833 2:49191004-49191004 2:48963865-48963865
22 FSHR NM_000145.4(FSHR):c.926G>T (p.Gly309Val)SNV Uncertain significance 895869 2:49191034-49191034 2:48963895-48963895
23 FSHR NM_000145.4(FSHR):c.898G>A (p.Glu300Lys)SNV Uncertain significance 896140 2:49191062-49191062 2:48963923-48963923
24 FSHR NM_000145.4(FSHR):c.707A>G (p.Tyr236Cys)SNV Uncertain significance 896141 2:49195984-49195984 2:48968845-48968845
25 FSHR NM_000145.4(FSHR):c.645C>T (p.His215=)SNV Uncertain significance 897743 2:49210074-49210074 2:48982935-48982935
26 FSHR NM_000145.4(FSHR):c.636T>C (p.Asp212=)SNV Uncertain significance 897744 2:49210083-49210083 2:48982944-48982944
27 FSHR NM_000145.4(FSHR):c.510T>G (p.Phe170Leu)SNV Uncertain significance 898895 2:49216130-49216130 2:48988991-48988991
28 FSHR NM_000145.4(FSHR):c.496G>T (p.Val166Leu)SNV Uncertain significance 898896 2:49216144-49216144 2:48989005-48989005
29 FSHR NM_000145.4(FSHR):c.455A>C (p.Gln152Pro)SNV Uncertain significance 895933 2:49216185-49216185 2:48989046-48989046
30 FSHR NM_000145.4(FSHR):c.351G>A (p.Gln117=)SNV Uncertain significance 895934 2:49244651-49244651 2:49017512-49017512
31 FSHR NM_000145.4(FSHR):c.180C>T (p.Val60=)SNV Uncertain significance 896209 2:49295402-49295402 2:49068263-49068263
32 FSHR NM_000145.4(FSHR):c.176G>A (p.Arg59Gln)SNV Uncertain significance 896210 2:49295406-49295406 2:49068267-49068267
33 FSHR NM_000145.4(FSHR):c.135G>A (p.Pro45=)SNV Uncertain significance 897816 2:49381422-49381422 2:49154283-49154283
34 FSHR NM_000145.4(FSHR):c.-96A>CSNV Uncertain significance 898968 2:49381652-49381652 2:49154513-49154513
35 FSHR NM_000145.4(FSHR):c.*173G>ASNV Uncertain significance 898763 2:49189699-49189699 2:48962560-48962560
36 FSHR NM_000145.4(FSHR):c.1902C>T (p.Arg634=)SNV Uncertain significance 895792 2:49190058-49190058 2:48962919-48962919
37 FSHR NM_000145.4(FSHR):c.1677C>T (p.Pro559=)SNV Uncertain significance 896078 2:49190283-49190283 2:48963144-48963144
38 FSHR NM_000145.4(FSHR):c.1664C>T (p.Thr555Ile)SNV Uncertain significance 896079 2:49190296-49190296 2:48963157-48963157
39 FSHR NM_000145.4(FSHR):c.1400G>T (p.Arg467Ile)SNV Uncertain significance 897666 2:49190560-49190560 2:48963421-48963421
40 FSHR NM_000145.4(FSHR):c.1173A>G (p.Gln391=)SNV Uncertain significance 897667 2:49190787-49190787 2:48963648-48963648
41 FSHR NM_000145.4(FSHR):c.1145T>C (p.Ile382Thr)SNV Uncertain significance 898830 2:49190815-49190815 2:48963676-48963676
42 FSHR NM_000145.4(FSHR):c.1094T>C (p.Leu365Pro)SNV Uncertain significance 898831 2:49190866-49190866 2:48963727-48963727
43 FSHR NM_000145.3(FSHR):c.399G>A (p.Lys133=)SNV Uncertain significance 595880 rs148815172 2:49217752-49217752 2:48990613-48990613
44 FSHR NM_000145.3(FSHR):c.1576T>C (p.Leu526=)SNV Uncertain significance 336481 rs138281715 2:49190384-49190384 2:48963245-48963245
45 FSHR NM_000145.3(FSHR):c.*199A>GSNV Uncertain significance 336477 rs886056148 2:49189673-49189673 2:48962534-48962534
46 FSHR NM_000145.3(FSHR):c.1831C>G (p.Leu611Val)SNV Uncertain significance 336479 rs886056149 2:49190129-49190129 2:48962990-48962990
47 FSHR NM_000145.3(FSHR):c.688A>G (p.Ile230Val)SNV Uncertain significance 336486 rs367711694 2:49196003-49196003 2:48968864-48968864
48 FSHR NM_000145.3(FSHR):c.219G>A (p.Glu73=)SNV Uncertain significance 336493 rs377397067 2:49295363-49295363 2:49068224-49068224
49 FSHR NM_000145.3(FSHR):c.-58T>CSNV Uncertain significance 336494 rs886056153 2:49381614-49381614 2:49154475-49154475
50 FSHR NM_000145.4(FSHR):c.*574T>CSNV Uncertain significance 897605 2:49189298-49189298 2:48962159-48962159

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

73
# Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279 rs121909665
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

Sources

Expression for Ovarian Hyperstimulation Syndrome

About this section
Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.
Sources

Pathways for Ovarian Hyperstimulation Syndrome

About this section

Pathways related to Ovarian Hyperstimulation Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

Pathways related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
p70S6K Signaling 63
Show member pathways
 12.96 REN KDR INS IL6 GNRH1 FLT1
2
cAMP signaling pathway 36
12.14 LHCGR FSHR FSHB CGA AMH
3
G alpha (s) signalling events 65
12.02 LHCGR FSHR FSHB CGA
4
Peptide hormone metabolism 65
Show member pathways
 11.98 REN INS FSHB CGB5 CGA
5
S1P3 pathway 1
Show member pathways
 11.87 VEGFA KDR FLT1 CDH5
6
HIF-1 signaling pathway 36
11.83 VEGFA INS IL6 FLT1
7
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.78 INS IL6 CDH5
8
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
11.78 VEGFA KDR INS IL6 ALB
9
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 65
Show member pathways
 11.76 VEGFA CGB5 CGA
10
Rheumatoid arthritis 36
11.76 VEGFA IL6 FLT1
11
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.72 VEGFA KDR FLT1 CDH5
12
Angiogenesis (CST) 4
11.68 REN KDR FLT1 CDH5
13
Transcription_P53 signaling pathway 22
11.63 VEGFA KDR FLT1 BMP15
14
Differentiation Pathway 1
11.45 VEGFA INS IL6
15
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.41 IL6 CYP19A1 CGA
16
Vemurafenib Pathway, Pharmacodynamics 60
11.39 VEGFA KDR FLT1
17
Signaling events mediated by TCPTP 1
Show member pathways
 11.37 VEGFA KDR INS
18
HIF-2-alpha transcription factor network 1
11.26 VEGFA KDR FLT1
19
Ovarian Infertility Genes 1
11.21 LHCGR FSHR CYP19A1
20
Angiogenesis (WikiPathways) 1
11.03 VEGFA KDR FLT1
21
G-protein signaling_Rap2B regulation pathway 22
10.92 KDR IL6 GNRH1 FLT1 CDH5 BMP15
22
Follicle Stimulating Hormone (FSH) signaling pathway 1
10.89 FSHR FSHB CYP19A1 CGA
23
Ovarian steroidogenesis 36
10.87 LHCGR INS FSHR FSHB CYP19A1 CGA
24
VEGF binds to VEGFR leading to receptor dimerization 65
Show member pathways
 10.75 VEGFA KDR FLT1
25
Hormone ligand-binding receptors 65
10.47 LHCGR GNRH1 FSHR FSHB CGA
Sources

GO Terms for Ovarian Hyperstimulation Syndrome

About this section

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 VEGFA REN INS IL6 GNRH1 FSHB
2 endoplasmic reticulum lumen GO:0005788 9.65 INS IL6 F5 BMP15 ALB
3 platelet alpha granule lumen GO:0031093 9.5 VEGFA F5 ALB
4 extracellular region GO:0005576 9.5 VEGFA SHBG REN KDR INS IL6
5 follicle-stimulating hormone complex GO:0016914 9.16 FSHB CGA

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.15 LHCGR INS GNRH1 FSHR FSHB CGB5
2 negative regulation of apoptotic process GO:0043066 10.03 VEGFA KDR IL6 GNRH1 ALB
3 positive regulation of gene expression GO:0010628 9.97 VEGFA INS IL6 FSHB CDH5 AMH
4 cell-cell signaling GO:0007267 9.92 INS GNRH1 CGB5 AMH
5 positive regulation of angiogenesis GO:0045766 9.87 VEGFA KDR FLT1 CDH5
6 positive regulation of cell proliferation GO:0008284 9.87 VEGFA KDR INS IL6 FSHB FLT1
7 cellular protein metabolic process GO:0044267 9.85 INS IL6 F5 BMP15 ALB
8 positive regulation of MAPK cascade GO:0043410 9.83 KDR INS IL6 FLT1
9 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.79 VEGFA KDR FLT1
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 KDR INS FSHR FLT1
11 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.72 VEGFA KDR FLT1
12 sprouting angiogenesis GO:0002040 9.71 VEGFA KDR FLT1
13 positive regulation of cell migration GO:0030335 9.7 VEGFA KDR INS FSHB FLT1 CGA
14 positive regulation of positive chemotaxis GO:0050927 9.63 VEGFA KDR
15 vascular wound healing GO:0061042 9.62 VEGFA KDR
16 peptide hormone processing GO:0016486 9.61 FSHB CGB5 CGA
17 Sertoli cell proliferation GO:0060011 9.6 FSHR FSHB
18 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.59 VEGFA KDR
19 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.58 VEGFA KDR
20 ovulation cycle process GO:0022602 9.58 LHCGR FSHR
21 vascular endothelial growth factor signaling pathway GO:0038084 9.58 VEGFA KDR FLT1
22 follicle-stimulating hormone signaling pathway GO:0042699 9.56 FSHR FSHB
23 female gamete generation GO:0007292 9.56 FSHR FSHB CGB5 BMP15
24 gonad development GO:0008406 9.54 FSHR CGA AMH
25 positive regulation of steroid biosynthetic process GO:0010893 9.51 FSHB CGA
26 hormone-mediated signaling pathway GO:0009755 9.35 REN LHCGR FSHR FSHB CGB5
27 ovarian follicle development GO:0001541 9.02 VEGFA LHCGR FSHR FSHB BMP15

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 VEGFA IL6 BMP15 AMH
2 vascular endothelial growth factor receptor 2 binding GO:0043184 9.4 VEGFA CDH5
3 protein-hormone receptor activity GO:0016500 9.37 LHCGR FSHR
4 vascular endothelial growth factor binding GO:0038085 9.32 KDR FLT1
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.26 KDR FLT1
6 hormone activity GO:0005179 9.1 INS GNRH1 FSHB CGB5 CGA AMH
7 follicle-stimulating hormone activity GO:0016913 8.96 FSHB CGA
Sources

Sources for Ovarian Hyperstimulation Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....